Navigation Links
Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification
Date:3/5/2009

mor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also has an in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: There can be no assurance that the Company will satisfy Nasdaq's conditions for continued listing on The Nasdaq Capital Market, that any potential appeal or hearing for a stay of delisting from The Nasdaq Capital Market will be successful, or that the Company's common stock will remain listed on The Nasdaq Capital Market; that the Company will complete cost-effective clinical trials or meet as anticipated the development timelines for the drug candidates in its pipeline, including Zerenex and KRX-0401, to help generate greater interest in the market for its common stock; that our statements regarding our balance sheet, operating results and 2009 cash burn rate will reflect our actual results; or that the Company's stock will not be affected by other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
2. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
4. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
5. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT
7. Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
8. Keryx Biopharmaceuticals Receives Nasdaq Notification
9. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
10. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014  Nektar Therapeutics (NASDAQ: ... characterizing the analgesic profiles of a series of ... agonist molecules. The preclinical research candidates were created ... The analgesic properties of kappa receptor ... 1,2 Kappa opioid receptors are expressed in ...
(Date:9/19/2014)... Dublin ... announced the addition of the  "Micro Market Monitor ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... fastest-growing segments in the chromatography market. The market ... expected to reach $2.0 billion by 2019, at ...
(Date:9/18/2014)... LONDON , Sept. 18, 2014 ... near-patient testing, is performed outside a clinical laboratory. ... hence in administrating appropriate treatments and medication. POCT ... and prevalence of lifestyle diseases such as diabetes, ... and user-friendly. POCT devices are standardized to minimize ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Texas ... John Sharp, Texas A&M Health Science Center CEO ... Department of Health and Human Services (HHS), State ... a national pandemic influenza vaccine manufacturing facility in ... an anchor for the Texas A&M Biocorridor – ...
Breaking Biology Technology:Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Micro Market Monitor : Global Pre-packed Chromatography Columns 2POCT Market in China 2014-2018 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4
... ... PharmSource Information Services, Inc. announces the publication of a ... How to Minimize Your Risk." This incisive resource provides guidelines on ... risk for companies doing business throughout the world. "The U.S. Foreign ...
... SAN DIEGO, INDIANAPOLIS and CAMBRIDGE, Mass., July 7 ... Lilly and Company (NYSE: LLY ) and Alkermes, ... New Drug Application (NDA) for exenatide once weekly has been ... (FDA). , , Exenatide once weekly is an investigational ...
... Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: ... Sun Pharmaceutical Industries Ltd. (Sun Pharma), immediately following Sun ... Drug Administration (FDA) for its Abbreviated New Drug Application ... tablets are an androgen receptor inhibitor indicated for use ...
Cached Biology Technology:PharmSource Releases White Paper on Role of U.S. Foreign Corrupt Practices Act (FCPA) in the Bio/Pharma Industry 2PharmSource Releases White Paper on Role of U.S. Foreign Corrupt Practices Act (FCPA) in the Bio/Pharma Industry 3New Drug Application for Exenatide Once Weekly Accepted for Review by FDA 2New Drug Application for Exenatide Once Weekly Accepted for Review by FDA 3New Drug Application for Exenatide Once Weekly Accepted for Review by FDA 4New Drug Application for Exenatide Once Weekly Accepted for Review by FDA 5New Drug Application for Exenatide Once Weekly Accepted for Review by FDA 6Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Casodex(R) Tablets 2
(Date:9/18/2014)... A team of researchers from McGill University and ... form of polyethylene ,microbeads, Canadian Journal of ... likely originate from cosmetics, household cleansers, or industrial ... abrasives. Owing to their small size and buoyancy, ... Microplastics are a global contaminant in the ...
(Date:9/18/2014)... DNA, tiny strands of nucleic acid that contain instructions ... genetic data, our DNA is copied into RNA molecules, ... tasks in our cells. , Several years ago, ... all other known RNAs, this molecule is circular, and ... little has been known about how they are produced. ...
(Date:9/18/2014)... from several disciplines will be celebrated tonight at the ... in improving the health of premature infants and in ... The researchers, whose work was supported by the National ... former Atomic Energy Commission, will be honored at a ... A bipartisan group of Members of Congress will be ...
Breaking Biology News(10 mins):Microplastic pollution discovered in St. Lawrence River sediments 2Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 23rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2
... that rising global temperatures accompanied by melting permafrost in ... into the atmosphere. Once released, that methane gas would ... radiation about 20 times more efficiently than does the ... appearing in the Journal of Geophysical Research ...
... that specially synthesized boron compounds are readily accepted in ... a proof of concept that could lead to new ... Oregon chemist Shih-Yuan Liu reported in the Journal ... of boron-nitrogen compounds with electronic and structural similarities to ...
... This release is available in German . ... restoration and maintenance of the Earth,s multi-trillion dollar ecosystems - ... can have a key role in countering climate change and ... of a new climate issues update by The Economics of ...
Cached Biology News:Methane gas likely spewing into the oceans through vents in sea floor 2Methane gas likely spewing into the oceans through vents in sea floor 3Boron-based compounds trick a biomedical protein 2Time to tap climate-change-combating potential of the world's ecosystems 2Time to tap climate-change-combating potential of the world's ecosystems 3Time to tap climate-change-combating potential of the world's ecosystems 4Time to tap climate-change-combating potential of the world's ecosystems 5